Clinical Utility of Postneoadjuvant Chemotherapy Computerized Tomography for Muscle Invasive Urothelial Bladder...

Area of Science:

• Oncology
• Radiology
• Urology

Background:

• Muscle-invasive bladder cancer (MIBC) management often involves neoadjuvant chemotherapy followed by cystectomy.
• Computerized tomography (CT) scans are crucial for pre-surgical planning in MIBC.
• Evaluating the utility of CT scans after neoadjuvant chemotherapy is essential for optimizing treatment pathways.

Purpose of the Study:

• To assess the clinical value of post-neoadjuvant chemotherapy CT scans in localized bladder cancer patients.
• To determine the impact of new findings on surgical decision-making and patient outcomes.
• To analyze the frequency and implications of changes observed on post-chemotherapy CT scans.

Main Methods:

• Retrospective analysis of 79 patients with T2-3N0 urothelial bladder cancer who received cisplatin-based neoadjuvant chemotherapy.
• Review of post-neoadjuvant chemotherapy CT scans to identify tumor progression, nodal involvement, metastatic disease, and non-cancer findings.
• Evaluation of subsequent surgical decisions and overall survival based on CT findings.

Main Results:

• New findings were observed in 21.5% of post-neoadjuvant chemotherapy CT scans.
• False-positive rates for nodal and metastatic disease were 100%.
• Only 3.8% of patients had cystectomy plans altered due to tumor progression; 100% underwent cystectomy. New findings did not correlate with overall survival but delayed surgery (p=0.014).

Conclusions:

• Post-neoadjuvant chemotherapy CT scans identify new findings in a significant percentage of bladder cancer cases.
• These findings rarely lead to changes in preoperative surgical plans and do not impact overall survival.
• The high rate of false positives and surgical delays associated with these scans warrant careful consideration in clinical practice.